WAVE Life Sciences (WVE) Tops Q2 EPS by 13c

WAVE Life Sciences (NASDAQ: WVE) reported Q2 EPS of ($0.20), $0.13 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $7.94 million.

For earnings history and earnings-related data on WAVE Life Sciences (WVE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Independent Bank receives regulatory approval for HCB Financial acquisition
• H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE)